Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 21/3/2018
SIETES contiene 92210 citas

<< anterior 21 a 40 de 160 siguiente >>
Presentar resultados
Seleccionar todas
21.Tiene citas relacionadas Cita con resumen
22. Cita con resumen
Anónimo. Xolair (omalizumab): drug safety communication - Slightly elevated risk of cardiovascular and cerebrovascular serious adverse events. FDA U.S. Food and Drug Administration 2014:26 de septiembre. [Ref.ID 97997]
23. Cita con resumen
Chiu WY, Chien JY, Yang WS, Juanq JM, Lee JJ, Tsai KS. The risk of osteonecrosis of the jaws in Taiwanese osteoporotic patients treated with oral alendronate or raloxifene.. J Clin Endocrinol Metab 2014;99:2729-35. [Ref.ID 97859]
24. Cita con resumen
Weich S, Pearce HL, Croft P, Singh S, Crome I, Bashford J, Frisher M. Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort study. BMJ 2014;348:g1996. [Ref.ID 97297]
25. Cita con resumen
Anónimo. Thalidomide: risk of second primary malignancies. Drug Safety Update 2013;6:mayo. [Ref.ID 95524]
26.Tiene citas relacionadas Cita con resumen
27. Cita con resumen
Spencer FA, Iorio A, You J, Murad MH, Schünemann HJ, Vandvik PO, Crowther MA, Pottie K, Lang ES, Meerpohl JJ, Falck-Ytter Y, Alonso-Coello P, Guyatt GH. Uncertainties in baseline risk estimates and confidence in treatment effects. BMJ 2012;345:18-21. [Ref.ID 94177]
28.Tiene citas relacionadas Cita con resumen
Herzig S, Rothberg M. Drug prophylaxis in general medical patients: does usage reflect the benefits and risks?. BMJ 2012;344:21-3. [Ref.ID 93191]
29. Cita con resumen
Prabakar I, Webb A. Emergency contraception. BMJ 2012;344:61-4. [Ref.ID 92653]
30. Cita con resumen
Moynihan R. Surrogates under scrutiny: fallible correlations, fatal consequences. BMJ 2011;343:d5160. [Ref.ID 91893]
31. Cita con resumen
Bolland MJ, Grey A. Data openness. Reporting of absolute risk. BMJ 2010;341:1063. [Ref.ID 89685]
32.Tiene citas relacionadas
Kleijer BC, Heerdink ER, van Marum RJ. Antipsychotics and venous thrombosis. Dutch experience differs. BMJ 2010;341:793. [Ref.ID 89507]
35.Tiene citas relacionadas Cita con resumen
Parker C, Coupland C, Hippisley-Cox J. Antipsychotic drugs and risk of venous thromboembolism: nested case-control study. BMJ 2010;341:641. [Ref.ID 89413]
36. Cita con resumen
Prothro C, Kudish K, Fiellin M, Meek J, Tellman N, Milewski M, Hogan B, Holtzman C, Danila R, Dunning L, Lynfield R, Scherzinger K, Connor W, Baumbach J, Giambrone GP, Zansky SM, Smith PF, Thomas A, Mosites E, Kirschke D, Viray M, Lewis P, Sejvar J, Baughman A, Vellozzi C, Fridkin S, Conner S, Morgan O, Lu P, Furlow C, Singleton JA, Hale CR, Kattan J, Murphree R, Oh JY, Wise M. Preliminary results: surveillance for Guillain-Barré syndrome after receipt of influenza A (H1N1) 2009 monovalent vaccine --- United States, 2009--2010. MMWR Morb Mortal Wkly Rep 2010;59:1-5. [Ref.ID 88533]
37. Cita con resumen
Hosseinpoor AR, AbouZahr C. Graphical presentation of relative measures of association. Lancet 2010;375:1254. [Ref.ID 88252]
38.Tiene citas relacionadas Cita con resumen
Schulz KF, Altman DG, Moher D, Fergusson D. CONSORT 2010 changes and testing blindness in RCTs. Lancet 2010;375:1144-6. [Ref.ID 88230]
39.Tiene citas relacionadas
Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:698-702. [Ref.ID 88189]
40.Tiene citas relacionadas
Antes G. The new CONSORT statement. BMJ 2010;340:666-7. [Ref.ID 88182]
Seleccionar todas
<< anterior 21 a 40 de 160 siguiente >>